Your gate­way

to finance

and inno­va­tion

in Cen­tral Europe


Sev­enth Cen­tral Euro­pean Life Sci­ence Invest­ment Conference

Hotel Stary, Krakow, 2527 Octo­ber 2017

    • Early bird registration

until 8th Sep­tem­ber 2017

1200 PLN + 23% VAT

or €340 + 23% VAT

    • Stan­dard registration

from 9th Sep­tem­ber 2017

2000 PLN + 23% VAT

or €570 + 23% VAT

    • Accom­pa­ny­ing persons

If you would like to bring a friend do please con­tact us.

If there is suf­fi­cient inter­est we will develop an

agenda for accom­pa­ny­ing persons.

There will be a mod­est fee.

    • Extra din­ner guest

270zl + 23% VAT

77 + 23% VAT

By reg­is­ter­ing you acknowl­edge that you have read the dis­claimer and under­stood the can­cel­la­tion policy

Pay­ment by bank trans­fer in Euros to: PKO Bank Pol­ski in Krakow

94 1440 1127 0000 0000 1386 1129

Pay­ment by bank trans­fer in Pol­ish zloty to: PKO Bank Pol­ski in Krakow

68 1440 1127 0000 0000 1134 2701



Pow­ered by BreezingForms


Sev­enth Cen­tral Euro­pean Life Sci­ence Invest­ment Conference

Hotel Stary, Krakow, 2527 Octo­ber 2017

This yearstheme:

“Invest­ment and com­mer­cial­iza­tion: time for inter­na­tion­al­iza­tion and collaboration”

Full agenda to be announce


        • dr-Gabor-Lamm
          Gabor Lamm
        • Roland-Kozlowski
          Roland Kozłowskim
        • Katarzyna-Koziak
          Katarzyna Koziak
        • Simon-Wallwork
          Simon Wall­work
        • Kevin-Johnson
          Kevin John­son

dr Gabor Lamm

Gabor Lamm

Dr Jonathan Gee Invest­ment Direc­tor SPARK Ven­ture Man­age­ment Ltd and SPARK Impact Ltd

Dr. Lamm (born 1967 in Budapest) is a grad­u­ate of Edin­burgh Uni­ver­sity (Bio­chem­istry) and holds a Ph.D. in Mol­e­c­u­lar Biol­ogy. After spend­ing three years as a research sci­en­tist at the Boehringer Ingel­heim Insti­tute of Mol­e­c­u­lar Pathol­ogy (IMP) in Vienna, Dr. Lamm joined Wacker Chemie, a major global sup­plier of sil­i­cone and poly­mer raw mate­ri­als and semi­con­duc­tors. At Wacker Chemie Dr. Lamm was Business-​Team Leader in the divi­sion spe­cial­is­ing in advanced ceramic com­po­nents for high-​tech appli­ca­tions. As of Octo­ber 2000 he is Man­ag­ing Direc­tor of EMBL Enter­prise Man­age­ment Tech­nol­ogy Trans­fer GmbH (EMBLEM), a 100% sub­sidiary of the Euro­pean Mol­e­c­u­lar Biol­ogy Lab­o­ra­tory (EMBL; http://​www​.embl​.org). Dr. Lamm is an alum­nus of the Euro­pean Mol­e­c­u­lar Biol­ogy Lab­o­ra­tory Ph.D. pro­gram and of the Boehringer Ingel­heim Fonds, on the advi­sory board of var­i­ous asso­ci­a­tions and start-​up com­pa­nies, co-​founder of the VC vehi­cle EMBL-​Ventures, and for­mer vice-​president (20022006) of the Asso­ci­a­tion of Euro­pean Sci­ence and Tech­nol­ogy Trans­fer Pro­fes­sion­als (ASTP).

Roland Kozłowski

Roland Kozłowski

Kozlowski received a first class hon­ours degree from the Uni­ver­sity of Bath and a PhD from the Uni­ver­sity of Cam­bridge. He is a ser­ial bioen­tre­pre­neur, investor and men­tor who has worked in the indus­try for over twenty five years. Roland was Chief Exec­u­tive Offi­cer of Lec­tus Ther­a­peu­tics and Sense Pro­teomic Lim­ited two ven­ture cap­i­tal backed com­pa­nies which he founded, built and sold. Dur­ing his career Roland has lead or played a key role in a many trans­ac­tions includ­ing com-​pany financ­ing, sale, pur­chase, financ­ing and in– and out-​licensing with a cumu­la­tive value of over $200m. Ear­lier in his career Roland ran Research Groups at the Uni­ver­sity of Oxford and Uni­ver­sity of Bris­tol where he pub­lished and patented in the life sci­ence field. He has been a Vis­it­ing Indus­trial Pro­fes­sor, served on, or advised the boards of sev­eral Euro­pean com­pa­nies and orga­ni­za­tions includ­ing the Bio-​Industry Asso­ci­a­tion in the UK. Presently he is pres­i­dent and owner of Life Sci­ence Biznes Con­sult­ing which spe­cial­izes in com­mer­cial­iz­ing tech­nol­ogy from emerg­ing economies par­tic­u­larly in Poland. He acts as advi­sor to the National Cen­tre of Research & Devel­op­ment in Poland and the Pol­ish Devel­op­ment Agency. He is a founder and lim­ited part­ner in Life Sci­ence Inno­va­tions a spe­cial­ist VC fund based in Poland, an advi­sor to Alder­ley Park Ven­tures (UK) and a num­ber of start-​up com­pa­nies who he also mentors.

Katarzyna Koziak

Katarzyna Koziak

Dr. Katarzyna Koziak is a grad­u­ate cum laude from the Depart­ment of Embry­ol­ogy at the Fac­ulty of Biol­ogy of Uni­ver­sity of War­saw. Already as a stu­dent of Prof. Andrzej Tarkowski she joined the research team of Jacques Tes­tart and Rene Fry­d­man in Paris, France, where she worked on gametes mat­u­ra­tion and clin­i­cal aspects of in vitro fer­til­iza­tion. After her return to Poland, dr. Koziak started to work at the Med­ical Uni­ver­sity of War­saw where she in 1994 obtained her Ph.D. cum laude pre­sent­ing a dis­ser­ta­tion on ery­thro­poi­etin pro­duc­tion in kid­ney trans­plant recip­i­ents. Her sci­en­tific career con­tin­ued in the United States, where she moved for a five-​year post­doc­toral train­ing at Har­vard Med­ical School. Work­ing in Sandoz-​founded Fritz Bach’s group dr. Koziak inves­ti­gated endothe­lial cell biol­ogy and was one of the dis­cov­er­ers of NTP­Dase I, the key endothe­lial enzyme reg­u­lat­ing vas­cu­lar coag­u­la­tion and home­osta­sis. Fol­low­ing her return to Poland, she con­tin­ued research on vas­cu­lar inflam­ma­tion and in 2006 defended cum laude a habil­i­ta­tion (D.Sc.) dis­ser­ta­tion. As an rec­og­nized and expe­ri­enced researcher dr. Koziak par­tic­i­pates as a prin­ci­pal inves­ti­ga­tor or co-​investigator in sev­eral research projects in fields of vas­cu­lar biol­ogy founded mostly by Pol­ish Com­mit­tee for Sci­en­tific Research, Euro­pean Coun­cil, Pol­ish National Sci­ence Cen­ter and Foun­da­tion of Pol­ish Sci­ence. Dr. Katarzyna Koziak co-​authored numer­ous research arti­cles, text books and patent appli­ca­tions. She is also a rec­og­nized aca­d­e­mic teacher, cur­rently respon­si­ble for spe­cial­ized cur­ricu­lum in bio­chem­istry for stu­dents of Med­ical Uni­ver­sity of War­saw. Dr. Koziak’s achieve­ments were rec­og­nized by Pol­ish author­i­ties – she received twice the award of Prime Min­is­ter of Poland.


Simon Wall­work

With over 28 years expe­ri­ence advis­ing on acqui­si­tions, dis­pos­als, pri­vate equity and pub­lic mar­ket trans­ac­tions, for a wide vari­ety of clients includ­ing pub­lic and pri­vate com­pa­nies, banks, ven­ture cap­i­tal funds and part­ner­ships, Simon also has con­sid­er­able client side expe­ri­ence spend­ing a num­ber of years work­ing in-​house with Pilk­ing­ton plc where he was involved in a num­ber of cross bor­der transactions.

Simon has worked in the life sci­ences sec­tor for over 20 years hav­ing acted on the list­ing of Oxford Mol­e­c­u­lar Group plc. He has acted for many com­pa­nies in the sec­tor from incor­po­ra­tion through fund­ing rounds to even­tual exit by way of sale or IPO. He has a deep under­stand­ing of the sec­tor and its key drivers.


Kevin John­son

Prior to co-​founding medicxi, Kevin was a part­ner with Index Ven­tures for 12 years, hav­ing joined the firm’s life sci­ences team in 2003. Kevin spear­headed Index’s very first exper­i­men­tal asset-​centric invest­ment, in Pan­Genet­ics, which was later acquired by Abbott Phar­ma­ceu­ti­cals. He is cur­rently chair­man of Lev­i­cept Ltd., Apcin­tex and Crescendo Bio­log­ics as well as being a board mem­ber of sev­eral other star­tups. Prior to join­ing Index, Kevin was with Cam­bridge Anti­body Tech­nol­ogy (CAT), where he was appointed Head of Research in 1994 and, in 1997, Research Direc­tor and Chief Tech­nol­ogy Offi­cer. He led the devel­op­ment of CAT’s plat­form tech­nolo­gies and their appli­ca­tion in the dis­cov­ery of a num­ber of human anti­bod­ies, two of which are now on the mar­ket: Humira (Abbott Phar­ma­ceu­ti­cals) and Benlysta (Glax­o­SmithK­line). Kevin was part of the man­age­ment team that floated CAT on the Lon­don Stock Exchange; it was sub­se­quently acquired by AstraZeneca. Kevin received a BSc in Mol­e­c­u­lar Biol­ogy from Edin­burgh Uni­ver­sity and a PhD from Cam­bridge University.


  • newsletter_luty_2017_a


Under con­struc­tion



Life Sci­ence Biznes Con­sult­ing LSBC Sp. z o. o. allows a change of reg­is­trant at no extra cost if the orig­i­nal reg­is­trant is unable to attend.

In the event of can­cel­la­tion of the Con­fer­ence by the orga­niz­ers all fees paid by del­e­gates will be returned in full although Life Sci­ence Biznes Con­sult­ing LSBC Sp. z o. o. is not respon­si­ble for any other finan­cial losses such as travel and hotel costs.

In the event that a del­e­gate or accom­pa­ny­ing per­son can­cels atten­dance at the con­fer­ence Life Sci­ence Biznes Con­sult­ing LSBC Sp. z o. o. will return 60% of the reg­is­tra­tion fee if atten­dance is can­celled before Fri­day 18 Sep­tem­ber 2015. There­after there will be no return of fees.

Life Sci­ence Biznes Con­sult­ing LSBC Sp. z o. o. is not liable in any way for any injuries, sick­ness or acci­dent or any costs incurred as a con­se­quence of such an event or any other losses to which a del­e­gate or accom­pa­ny­ing per­son may be sub­jected to whist trav­el­ling to or from Poland or whilst attend­ing the con­fer­ence in Krakow or any of the social events organized.

The speak­ers listed have all con­firmed their atten­dance and have agreed to post their pho­tographs on this web­site. How­ever Life Sci­ence Biznes Con­sult­ing LSBC Sp. z o. o. informs del­e­gates and speak­ers that that the final agenda could change for rea­sons beyond its con­trol. Life Sci­ence Biznes Con­sult­ing LSBC Sp. z o. o. reserves the right to make changes to the agenda and is not respon­si­ble for any finan­cial losses or costs incurred by par­tic­i­pants or del­e­gates in asso­ci­a­tion with their par­tic­i­pa­tion at this conference.



selvitalogo selvitalogo




malopolska centre of biotechnology logo

media part­ner

biotechnologia dolina bio technologiczna pl logo
European Biotechnology Network


Under con­struc­tion


Under con­struc­tion